Search results
Results from the WOW.Com Content Network
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. [6] For osteoporosis it is less preferred than bisphosphonates . [ 6 ]
pimobendan – phosphodiesterase 3 inhibitor used to manage heart failure in dogs; pirlimycin – antimicrobial; ponazuril – anticoccidial; praziquantel – treatment of infestations of the tapeworms Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus; prazosin – sympatholytic used in hypertension and abnormal muscle contractions
Grapiprant is widely accepted in veterinary medicine due to its specific and targeted approach to pain management in dogs. The serum concentration of grapiprant is increased when used in conjunction with other drugs such as acetaminophen, albendazole, and alitretinoin. [citation needed]
The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen. [6] [7] Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive breast cancer. [8]
A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. [47]
Estradiol was used as a positive control and raloxifene was used because it is in the same drug class as ospemifene. [10] Multiple doses of oral ospemifene were tested. [10] 10 mg/kg/day of Ospemifene was found to cause a greater increase in vaginal weight and vaginal epithelial height than 10 mg/kg/day of raloxifene. [10]
Deracoxib is a coxib class nonsteroidal anti-inflammatory drug (NSAID). [3] Like other NSAIDs, its effects are caused by inhibition of cyclooxygenase (COX) enzymes. [7] At the doses used to treat dogs, deracoxib causes greater inhibition of COX-2 than of COX-1, [3] but at doses twice those recommended for use in dogs, deracoxib significantly inhibits COX-1 as well.
Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...